Evidence-based recommendations on Kurin Lock for blood culture collection.


NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.

Guidance development process

How we develop NICE medical technologies guidance

If a technology is recommended for use, the specific recommendations are not intended to limit use of other relevant technologies that may offer similar advantages. If the technology is recommended for further evidence generation, it can be used in the NHS to generate further evidence. NICE will review the guidance once new evidence is available. The recommendations are not intended to preclude the use of the technology but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.

This guidance replaces NICE’s medtech innovation briefing on Kurin Lock for blood culture collection (MIB297).

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.